Suggestions
Alain Huriez
Chairman and Managing Partner at AdBio partners
Alain Huriez is a seasoned professional in the Life Sciences sector, currently serving as a Venture Partner at Advent Life Sciences since January 2022. He has an extensive background, bringing over 32 years of experience to the field.
Career Overview
-
Early Career: Alain began his professional journey in the mid-1980s as the head of the emergency room at a large teaching hospital in France. He practiced as a General Practitioner for four years before transitioning into the biotechnology sector.
-
Biotechnology Experience: He spent 12 years at Quintiles (now IQVIA) as Vice President of Biotechnology in Europe, focusing on drug development and regulatory strategies. Following this, he became an entrepreneur, co-founding several biotechnology companies and serving as CEO of Neovacs and TcLand.
-
Leadership Roles: Alain has held various leadership positions, including:
- Chairman and Managing Partner at AdBio Partners since November 2015.
- President of Fondation Albert Gleizes since November 2006.
- Chairman of the Board at Orphalan from March 2015 to August 2022.
-
Founding EPEMED: He is also known for founding and chairing the European Personalized Medicine Association (EPEMED), emphasizing his commitment to precision medicine.
Contributions to Advent Life Sciences
Alain joined Advent Life Sciences in 2012 and later founded AdBio Partners in 2016, where he manages early-stage life sciences seed funds. His role involves identifying promising investment opportunities within the biotechnology landscape.
Through his extensive career, Alain Huriez has significantly impacted the biotechnology sector, particularly in Europe, by fostering innovation and supporting new ventures.
Highlights
Delighted to announce that Augustine Therapeutics is writing a new chapter of its development! Bravo to the team, congratulations to Gerhard Koenig as new exec chairman, welcome on board new investors Asabys and Eli Lilly! Augustine Therapeutics, Gerhard Koenig, Sylvain Celanire, Clara Campàs Moya, Asabys Partners, Eli Lilly and Company, VIB
🚨🚨 AdBio Partners et Inserm Transfert annoncent la création d’AndzonBio, une suite de start-up studios thématiques. 🤔 Andzon…, vous voulez dire « Hands-on » ? Oui c’est justement cela la définition d’une implication forte (et passionnée) pour transformer l’innovation de rupture en société de biotech, accélérer son développement précoce, poser les jalons du succès ! 🤗 Nous sommes très heureux chez AdBio d’annoncer cette nouvelle étape ambitieuse de notre engagement sur le segment le plus précoce de la création d’entreprise : la création de plusieurs start-ups studios thématiques thérapeutiques en biotech. 🤝Cette initiative traduit le renforcement de notre partenariat de longue durée avec Inserm Transfert. Elle répond à un besoin marché, à un constat fait ensemble : celui d'un effort supplémentaire à fournir pour bâtir un écosystème français puissant et souverain en sciences de la vie! C'est aujourd'hui nécessaire pour accélérer la transformation de l'excellence de la recherche française en traitements innovants pour les patients! Pascale Auge, Didier Samuel, Noémie Pellegrin, Armelle Sérose, Ph.D. Thomas Lombes, Franck Mouthon, Frédéric Girard, Lise ALTER, Agence de l'innovation en santé, Bpifrance, Inserm Transfert, INSERM , AdBio partners
